Feature Oragenics developing novel therapeutics using synthetic bacteria By Abby Hardy Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections... May 28, 2019